NEUROTROPE INC. overview

Vancouver, Canada (ABN Newswire) - Join Ellis Martin for an exclusive conversation pertinent to the world of the disruptive disease called Alzheimers. Can this dreadful malady be reversed offering hope to victims and their families? Can neurons in the brain be regrown? Is there a cure for Alzheimers? And what about stroke victims or those afflicted with Multiple Sclerosis? An American biotech company called Neurotrope (NASDAQ:NTRP) believes it has this proprietary platform technology with a...

Results Pave the Way for Future, Larger Trials NEW YORK, NY / ACCESSWIRE / May 2, 2017 / A new world of clinical trial data testing is upon us. Older methods to determine a drug's worth, are being replaced by more robust, accurate methods that, through advanced computing, better predict future results. A pioneer using 'modified intent-to-treat' (mITT) analysis, Neurotrope, Inc. (NTRP) released its first top-line results for lead compound Bryostatin in very sick Alzheimer's Disease ((AD))...

Top Line Data Expected in April 2017 in Placebo Controlled Study of Bryostatin-1 in 148 Moderate to Severe Alzheimer's Patients NEW YORK, NY / ACCESSWIRE / April 4, 2017 / Too much modern medicine relies on treating symptoms, not underlying cause. This is especially clear with Alzheimer's Disease ((AD)), where 5.4 million Americans and 44 million people worldwide suffer in a market of $236 billion here and $605 billion globally. Old drugs do not work. Needed now is something new, especially in...